FY16 Results Presentation
Sydney, Aug 24, 2016 AEST (ABN Newswire) - Regeneus Ltd (
ASX:RGS) are pleased to provide a Company Presentation for the Full Year Results for FY16.
FY16 Financial Results Overview
- Licence fee revenues up 35% to $1.2m (FY15: $0.9m)
- R&D tax incentive of $2.7m claimed (FY15: $3.4m)
- Expenditure levels reduced in all categories a key benefit of the strategic changes taken throughout FY15
- Loss from ordinary activities reduced by 45% to $3.6 m (FY15: $6.6m)
Operating Cash Burn
- Quarterly cash burn down 37% to $1.48m per quarter (FY15: $2.35m per quarter) - better than stated target of $1.7m
- Net cash used in operating activities of $2.25m (including R&D tax incentive) (FY15: $5.92m)
- $2m R&D tax funding facility in place
- R&D tax incentive of $2.7m expected to be received mid September '16
Progenza FY16 Achievements
STEP Trial Update
- Commenced and completed recruitment for Progenza Phase 1 Study for osteoarthritis (STEP Trial)
- Positive safety review for both cohorts
- 12 month follow up on participants
Collaboration and licensing
- Progressed licensing discussions for manufacturing, clinical development and commercialisation in Japan
Product development and scale-up
- Collaboration with CSIRO on manufacture scale up-technologies
- Improvements to cell growth media to enhance yield
- Developed potency and identity assays
RGSH4K - Human Cancer Vaccine FY16 Achievements
- Established tumour bank - receiving patient samples to support vaccine manufacture
- First patient dosed safely Nov '15 - ACTIVATE trial open for enrollment
- Patients dosed safely in all 3 cohorts
- Assess emerging study data to:
-- investigate vaccine safety, and
-- identify a biologically active dose for further studies
- Exploring partnering for combination with check point inhibitors
CryoShot FY16 Achievements
- Commenced recruitment for 80 dog prepivotal trial at U.Penn to assess CryoShot for canine osteoarthritis more than 30% recruited
- Entered into agreement with top animal health pharma to partner development and commercialisation of CryoShot
- Positive clinical results for using CryoShot on early orthopaedic development disease in yearling thoroughbreds
- Commenced study in assessing CryoShot for strengthening equine tendons
Kvax - Canine Cancer Vaccine FY16 Achievements
- Completed clinical trial assessing Kvax for canine osteosarcoma as standalone treatment with Dr Bergman of VCA Hospital Inc., largest US vet services group
-- data readout from osteosarcoma trial in Oct '16
- Commenced clinical trial for Kvax in combination with chemotherapy for canine lymphoma with SASH
To view the full presentation, please visit:
http://abnnewswire.net/lnk/E733157G
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
| ||
|
